Home › Compare › JDEPF vs ABBV
JDEPF yields 2.23% · ABBV yields 3.06%● Live data
📍 JDEPF pulled ahead of the other in Year 4
Combined, JDEPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JDEPF + ABBV for your $10,000?
JDE Peet's N.V., together with its subsidiaries, provides various coffee and tea products and solutions to serve consumer needs worldwide. The company operates through CPG Europe, CPG LARMEA, CPG APAC, Out-of-Home, and Peet's segments. It offers multi-serve coffee, and single-serve and double-shot coffee capsules; and pads and pods, instant coffee, whole beans, ready-to-drink coffee beverages, various leaf and packaged tea, and professional tea products, as well as rents or sells professional solutions and complementary coffee systems. The company sells its products under the Douwe Egberts, Kenco, Peet's, L'OR, Stumptown, TiOra, Gevalia, Pickwick, PILAO, Intelligentsia, Senseo, Jacobs, Moccona, Super, OldTown, Ofçay, Mighty Leaf Tea, and Tassimo brands through CPG and out-of-home sales channels. It operates 505 coffee stores under the Peet's, Intelligentsia, Stumptown, OldTown, and 12Oz brands in the United States, China, Malaysia, and Italy, as well as through webshops, and third-party e-tailers and e-commerce marketplaces. The company serves various businesses, such as hotels, hospitals, restaurants, cruise liners, and retirement homes, as well as distributors for distribution to the customer; and offices, universities, airports, and sports venues. JDE Peet's N.V. was incorporated in 2018 and is headquartered in Amsterdam, the Netherlands.
Full JDEPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.